These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 38762484)

  • 1. Regulatory mechanisms of PD-1/PD-L1 in cancers.
    Lin X; Kang K; Chen P; Zeng Z; Li G; Xiong W; Yi M; Xiang B
    Mol Cancer; 2024 May; 23(1):108. PubMed ID: 38762484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the "all-around warrior" in immunotherapy.
    Liu Q; Guan Y; Li S
    Mol Cancer; 2024 Sep; 23(1):183. PubMed ID: 39223527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
    Hack SP; Zhu AX; Wang Y
    Front Immunol; 2020; 11():598877. PubMed ID: 33250900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
    Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
    Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
    [No Abstract]   [Full Text] [Related]  

  • 5. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment.
    Hudson K; Cross N; Jordan-Mahy N; Leyland R
    Front Immunol; 2020; 11():568931. PubMed ID: 33193345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-Talks between Raf Kinase Inhibitor Protein and Programmed Cell Death Ligand 1 Expressions in Cancer: Role in Immune Evasion and Therapeutic Implications.
    Ho M; Bonavida B
    Cells; 2024 May; 13(10):. PubMed ID: 38786085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms Controlling PD-L1 Expression in Cancer.
    Cha JH; Chan LC; Li CW; Hsu JL; Hung MC
    Mol Cell; 2019 Nov; 76(3):359-370. PubMed ID: 31668929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
    Chen J; Jiang CC; Jin L; Zhang XD
    Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
    Ai L; Xu A; Xu J
    Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 and its ligands are important immune checkpoints in cancer.
    Dong Y; Sun Q; Zhang X
    Oncotarget; 2017 Jan; 8(2):2171-2186. PubMed ID: 27974689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.
    Yin Z; Yu M; Ma T; Zhang C; Huang S; Karimzadeh MR; Momtazi-Borojeni AA; Chen S
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications.
    Ortega MA; Boaru DL; De Leon-Oliva D; Fraile-Martinez O; García-Montero C; Rios L; Garrido-Gil MJ; Barrena-Blázquez S; Minaya-Bravo AM; Rios-Parra A; Álvarez-Mon M; Jiménez-Álvarez L; López-González L; Guijarro LG; Diaz R; Saez MA
    J Mol Med (Berl); 2024 Aug; 102(8):987-1000. PubMed ID: 38935130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
    Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
    J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
    Jiang Y; Zhan H
    Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.
    Wu Y; Chen W; Xu ZP; Gu W
    Front Immunol; 2019; 10():2022. PubMed ID: 31507611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy.
    Jiang W; Pan S; Chen X; Wang ZW; Zhu X
    Mol Cancer; 2021 Sep; 20(1):116. PubMed ID: 34496886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of programmed death-ligand 1 expression in response to DNA damage in cancer cells: Implications for precision medicine.
    Sato H; Jeggo PA; Shibata A
    Cancer Sci; 2019 Nov; 110(11):3415-3423. PubMed ID: 31513320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors.
    Wei Y; Xiao X; Lao XM; Zheng L; Kuang DM
    Cell Mol Life Sci; 2021 Feb; 78(3):867-887. PubMed ID: 32940722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.